



# SPAFID CONNECT

Informazione Regolamentata n. 0472-2-2018	Data/Ora Ricezione 11 Gennaio 2018 15:59:45	MTA - Star
---	---	------------

Societa' : BB BIOTECH

Identificativo : 97909

Informazione  
Regolamentata

Nome utilizzatore : BIOTECHNSS01 - Alderuccio

Tipologia : REGEM

Data/Ora Ricezione : 11 Gennaio 2018 15:59:45

Data/Ora Inizio : 11 Gennaio 2018 15:59:46

Diffusione presunta

Oggetto : Corporate events calendar 2018

*Testo del comunicato*

Vedi allegato.



**Press Release, January 11, 2018**

## **Corporate events calendar – 2018**

19/01/2018	Portfolio as of December 31, 2017
16/02/2018	Annual Report 2017
13/03/2018	Annual General Meeting <i>Park Casino, Steigstrasse 26, 8200 Schaffhausen h. 3 pm</i>
27 - 28/03/2018	STAR Conference 2018 - Milan
20/04/2018	Interim Report as of March 31, 2018
20/07/2018	Interim Report as of June 30, 2018
19/10/2018	Interim Report as of September 30, 2018

The dates of the meetings with the financial community will be made public later on.

### **For further information:**

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland  
Tanja Chicherio, Tel. +41 44 267 67 07, [tch@bellevue.ch](mailto:tch@bellevue.ch)  
[www.bbbiotech.com](http://www.bbbiotech.com)

### **Company profile**

BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector with approx. CHF 3.5 billion in assets under management. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.

Fine Comunicato n.0472-2

Numero di Pagine: 3